This website uses cookies to enhance the user experience.
RISE PFI AS

RISE PFI AS986 164 901

Research
Limited company
Høgskoleringen 6B 7034 TRONDHEIM, Norge

RISE PFI AS

Novel and sustainable products - RISE PFI AS
RISE PFI is an internationally research institute. We develop novel and sustainable products and solutions for the future biobased society.

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Links

Organization

Chairman of the board
Years since formation
22 years
since Oct 27, 2003
Type
Limited company
VAT registered
Yes
Number of employees
28

Ownership

Number of shares and share classes
200
1 share class
Total number of shareholders
2
1 company, 1 person

Financials

Total operating income 2024
59,197,162
NOK
Annual total result 2024
2,408,992
NOK
Total equity 2024
35,762,190
NOK
Last update: Jun 13, 2025

Management

Management / administration

NameRoleShares
Managing Director/CEO-

Board

NameRoleShares
Chairman-
Board Member-
KT
Board Member-
Board Member-
Alternate Member-
Deputy Chair-
Board Member-

Others

NameRoleShares
B
BDO AS
Auditor-
T
TIETOEVRY ACCOUNTING AS
Accountant-
Last update: Feb 6, 2025

Ownership

Company shareholders

NameShare classTotal number of sharesShare
Ordinary shares
190
95 %
Ordinary shares
10
5 %
Last update: Jun 2, 2025

Financials

in NOK

Summary

Year2024202320222021
Total operating income
59,197,162
52,181,379
49,048,021
46,225,952
Annual Total Result
2,408,992
2,539,590
3,130,016
3,205,684
Total assets
65,367,880
55,387,738
51,726,085
54,704,425
Total liabilities
29,605,690
22,034,540
20,912,477
27,020,833
Total equity
35,762,190
33,353,198
30,813,608
27,683,592

P&L

Year2024202320222021
Total operating income
59,197,162
52,181,379
49,048,021
46,225,952
Total operating costs
56,922,197
49,377,240
45,056,660
42,149,401
Operating result
2,274,965
2,804,139
3,991,361
4,076,551
Financial income/costs
829,707
467,021
39,676
33,300
Profit before tax
3,104,672
3,271,160
4,031,037
4,109,851
Total tax & extraordinary income/cost
695,680
731,570
901,021
904,167
Annual Total Result
2,408,992
2,539,590
3,130,016
3,205,684

Balance overview

Year2024202320222021
Total fixed assets
1,153,875
1,112,285
817,695
916,470
Total current assets
64,214,005
54,275,453
50,908,390
53,787,955
Total assets
65,367,880
55,387,738
51,726,085
54,704,425
Short term debt
29,605,690
22,034,540
20,912,477
27,012,266
Long term debt
0
0
0
8,567
Total liabilities
29,605,690
22,034,540
20,912,477
27,020,833
Contributed capital
200,000
200,000
200,000
200,000
Retained earnings
35,562,190
33,153,198
30,613,608
27,483,592
Total equity
35,762,190
33,353,198
30,813,608
27,683,592
Total equity and liabilities
65,367,880
55,387,738
51,726,085
54,704,425

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology